STRYKER CORP (SYK) Spending and interest coverage
- R&D / revenue · 12 months: Value 6.42%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.97%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 6.42% | Research and development expense / revenue. Period ending 2026-06-30. $1.66B ÷ $25.84B × 100 ≈ 6.42% |
| Stock-based compensation / revenue · 12 months | 0.97% | Share-based compensation / revenue. Period ending 2026-06-30. $251.00M ÷ $25.84B × 100 ≈ 0.97% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.66B USD | Research and Development Expense |
| Revenue | 25.84B USD | |
| Stock-based compensation | 251.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 5.53B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.66B | $25.84B | $251.00M | $5.53B | (m) | 6.42% | 0.97% | (m) | (m) |
| 2026-03-31 | $1.63B | $25.27B | $246.00M | $4.99B | (m) | 6.45% | 0.97% | (m) | (m) |
| 2025-12-31 | $1.62B | $25.12B | $243.00M | $4.89B | (m) | 6.46% | 0.97% | (m) | (m) |
| 2025-09-30 | $1.58B | $24.38B | $240.00M | $3.67B | (m) | 6.48% | 0.98% | (m) | (m) |
| 2025-06-30 | $1.55B | $23.82B | $229.00M | $3.62B | (m) | 6.50% | 0.96% | (m) | (m) |
| 2025-03-31 | $1.50B | $23.22B | $226.00M | $3.55B | (m) | 6.47% | 0.97% | (m) | (m) |
| 2024-12-31 | $1.47B | $22.59B | $229.00M | $3.69B | (m) | 6.49% | 1.01% | (m) | (m) |
| 2024-09-30 | $1.46B | $21.97B | $224.00M | $4.37B | (m) | 6.64% | 1.02% | (m) | (m) |
| 2024-06-30 | $1.43B | $21.39B | $225.00M | $4.21B | (m) | 6.70% | 1.05% | (m) | (m) |
| 2024-03-31 | $1.42B | $20.96B | $218.00M | $4.13B | (m) | 6.76% | 1.04% | (m) | (m) |
| 2023-12-31 | $1.39B | $20.50B | $205.00M | $3.89B | (m) | 6.77% | 1.00% | (m) | (m) |
| 2023-09-30 | $1.36B | $19.89B | $193.00M | $3.44B | (m) | 6.86% | 0.97% | (m) | (m) |
| 2023-06-30 | $1.38B | $19.45B | $174.00M | $3.32B | (m) | 7.07% | 0.89% | (m) | (m) |
| 2023-03-31 | $1.38B | $18.95B | $171.00M | $3.13B | (m) | 7.28% | 0.90% | (m) | (m) |
| 2022-12-31 | $1.45B | $18.45B | $168.00M | $2.84B | (m) | 7.88% | 0.91% | (m) | (m) |
| 2022-09-30 | $1.46B | $17.95B | $170.00M | $2.85B | (m) | 8.13% | 0.95% | (m) | (m) |
| 2022-06-30 | $1.40B | $17.63B | $171.00M | $2.61B | (m) | 7.95% | 0.97% | (m) | (m) |
| 2022-03-31 | $1.36B | $17.43B | $174.00M | $2.57B | (m) | 7.80% | 1.00% | (m) | (m) |
| 2021-12-31 | $1.24B | $17.11B | $171.00M | $2.58B | (m) | 7.22% | 1.00% | (m) | (m) |
| 2021-09-30 | $1.16B | $16.67B | $168.00M | $2.51B | (m) | 6.95% | 1.01% | (m) | (m) |
| 2021-06-30 | $1.09B | $16.25B | $163.00M | $2.80B | (m) | 6.74% | 1.00% | (m) | (m) |
| 2021-03-31 | $1.02B | $14.72B | $154.00M | $2.05B | (m) | 6.92% | 1.05% | (m) | (m) |
| 2020-12-31 | $984.00M | $14.35B | $142.00M | $2.22B | (m) | 6.86% | 0.99% | (m) | (m) |
| 2020-09-30 | $983.00M | $14.22B | $147.00M | $2.42B | (m) | 6.91% | 1.03% | (m) | (m) |
| 2020-06-30 | $987.00M | $14.07B | $150.00M | $2.19B | (m) | 7.01% | 1.07% | (m) | (m) |
| 2020-03-31 | $1.00B | $14.96B | $148.00M | $2.82B | (m) | 6.69% | 0.99% | (m) | (m) |
| 2019-12-31 | $971.00M | $14.88B | $127.00M | $2.71B | (m) | 6.52% | 0.85% | (m) | (m) |
| 2019-09-30 | $938.00M | $14.55B | $127.00M | $2.47B | (m) | 6.45% | 0.87% | (m) | (m) |
| 2019-06-30 | $913.00M | $14.20B | $125.00M | $2.42B | (m) | 6.43% | 0.88% | (m) | (m) |
| 2019-03-31 | $883.00M | $13.88B | $125.00M | $2.47B | (m) | 6.36% | 0.90% | (m) | (m) |
| 2018-12-31 | $862.00M | $13.60B | $119.00M | $2.54B | (m) | 6.34% | 0.87% | (m) | (m) |
| 2018-09-30 | $846.00M | $13.28B | $115.00M | $2.55B | (m) | 6.37% | 0.87% | (m) | (m) |
| 2018-06-30 | $823.00M | $13.04B | $112.00M | $2.50B | (m) | 6.31% | 0.86% | (m) | (m) |
| 2018-03-31 | $799.00M | $12.73B | $110.00M | $2.33B | (m) | 6.28% | 0.86% | (m) | (m) |
| 2017-12-31 | $787.00M | $12.44B | $113.00M | $2.29B | (m) | 6.32% | 0.91% | (m) | (m) |
| 2017-09-30 | $771.00M | $12.13B | $111.00M | $2.24B | (m) | 6.36% | 0.92% | (m) | (m) |
| 2017-06-30 | $757.00M | $11.96B | $106.00M | $2.20B | (m) | 6.33% | 0.89% | (m) | (m) |
| 2017-03-31 | $748.00M | $11.79B | $101.00M | $2.20B | (m) | 6.35% | 0.86% | (m) | (m) |
| 2016-12-31 | $715.00M | $11.32B | $97.00M | $2.17B | (m) | 6.31% | 0.86% | (m) | (m) |
| 2016-09-30 | $690.00M | $10.88B | $92.00M | $2.15B | (m) | 6.34% | 0.85% | (m) | (m) |
| 2016-06-30 | $661.00M | $10.47B | $91.00M | $2.04B | (m) | 6.31% | 0.87% | (m) | (m) |
| 2016-03-31 | $632.00M | $10.06B | $91.00M | $1.97B | (m) | 6.28% | 0.90% | (m) | (m) |
| 2015-12-31 | $625.00M | $9.95B | $86.00M | $1.86B | (m) | 6.28% | 0.86% | (m) | (m) |
| 2015-09-30 | $614.00M | $9.85B | $84.00M | $1.68B | (m) | 6.23% | 0.85% | (m) | (m) |
| 2015-06-30 | $612.00M | $9.82B | $80.00M | $1.75B | (m) | 6.23% | 0.81% | (m) | (m) |
| 2015-03-31 | $616.00M | $9.75B | $79.00M | $1.52B | (m) | 6.32% | 0.81% | (m) | (m) |
| 2014-12-31 | $614.00M | $9.68B | $77.00M | $1.25B | (m) | 6.35% | 0.80% | (m) | (m) |
| 2014-09-30 | $600.00M | $9.53B | $77.00M | $1.21B | (m) | 6.30% | 0.81% | (m) | (m) |
| 2014-06-30 | $583.00M | $9.29B | $79.00M | $908.00M | (m) | 6.28% | 0.85% | (m) | (m) |
| 2014-03-31 | $557.00M | $9.14B | $77.00M | $1.00B | (m) | 6.10% | 0.84% | (m) | (m) |
| 2013-12-31 | $536.00M | $9.02B | $76.00M | $1.26B | (m) | 5.94% | 0.84% | (m) | (m) |
| 2013-09-30 | $526.00M | $8.89B | $75.00M | $1.20B | (m) | 5.92% | 0.84% | (m) | (m) |
| 2013-06-30 | $504.00M | $8.79B | $74.00M | $1.50B | (m) | 5.73% | 0.84% | (m) | (m) |
| 2013-03-31 | $488.00M | $8.69B | $74.00M | $1.65B | (m) | 5.62% | 0.85% | (m) | (m) |
| 2012-12-31 | $471.00M | $8.66B | $75.00M | $1.74B | (m) | 5.44% | 0.87% | (m) | (m) |
| 2012-09-30 | $457.00M | $8.53B | $74.00M | $1.79B | (m) | 5.36% | 0.87% | (m) | (m) |
| 2012-06-30 | $465.00M | $8.51B | $75.00M | $1.78B | (m) | 5.46% | 0.88% | (m) | (m) |
| 2012-03-31 | $463.00M | $8.45B | $76.00M | $1.74B | (m) | 5.48% | 0.90% | (m) | (m) |
| 2011-12-31 | $462.00M | $8.31B | $75.00M | $1.69B | (m) | 5.56% | 0.90% | (m) | (m) |
| 2011-09-30 | $457.90M | $8.09B | $73.80M | $1.65B | (m) | 5.66% | 0.91% | (m) | (m) |
| 2011-06-30 | $434.70M | $7.82B | $71.40M | $1.68B | (m) | 5.56% | 0.91% | (m) | (m) |
| 2011-03-31 | $414.80M | $7.54B | $69.60M | $1.73B | (m) | 5.50% | 0.92% | (m) | (m) |
| 2010-12-31 | $393.90M | $7.32B | $68.80M | $1.75B | (m) | 5.38% | 0.94% | (m) | (m) |
| 2010-09-30 | $372.70M | $7.16B | $68.90M | $1.88B | (m) | 5.21% | 0.96% | (m) | (m) |
| 2010-06-30 | $357.80M | $7.04B | $66.70M | $1.72B | (m) | 5.08% | 0.95% | (m) | (m) |
| 2010-03-31 | $345.80M | $6.92B | $64.40M | $1.66B | (m) | 5.00% | 0.93% | (m) | (m) |
| 2009-12-31 | $336.20M | $6.72B | $62.30M | $1.59B | (m) | 5.00% | 0.93% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $367.80M | $6.72B | $65.50M | $1.52B | (m) | 5.47% | 0.97% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $375.30M | $6.00B | $61.30M | $1.31B | (m) | 6.25% | 1.02% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| BOSTON SCIENTIFIC CORP (BSX) | United States | $64.781B | 17.29 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |